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Ewing’s sarcoma is characterized by the presence of fusion oncoproteins involving EWSR1 and an ETS gene, most com-
monly FLI1. In this issue of Cancer Cell, Smith et al. have combined RNA interference with expression profiling to study the 
pattern of gene expression downstream of the most common of these fusions, EWS/FLI. Using this strategy, Smith et al. have 
identified a homeobox gene, NKX2.2, which is both highly expressed in Ewing’s sarcoma and essential for the transforming 
activity of EWS/FLI.Ewing’s sarcoma (ES) is a rare cancer of 
children and young adults. It arises most 
frequently in bones, but it also can occur 
in a variety of soft tissue sites. It has a high 
propensity for metastasis, particularly to 
lung, bone, and bone marrow. While some 
patients can be cured with multimodal-
ity therapy, the substantial proportion of 
patients with metastatic disease usually 
present an insuperable clinical problem. 
Our understanding of ES biology is a tan-
talizing mix of knowledge and ignorance. 
For example, the cell of origin of ES is 
unknown as is the reason for its pecu-
liar anatomic distribution. Although ES 
expresses some neural markers, there is 
no evidence that ES arises from a neural 
progenitor. In contrast, a great insight into 
ES biology came with the discovery that 
ES tumors typically express a chimeric 
transcription factor derived from EWSR1 
and FLI1 (May et al., 1993; Delattre et al., 
1992). This fusion forms as a result of the 
translocation between chromosomes 11 
and 22 commonly observed in ES. FLI1 is 
a member of the ETS family of transcrip-
tion factors, and those ES tumors that lack 
the EWS/FLI fusion typically have a vari-
ant translocation involving one of several 
other ETS family members, most com-
monly ERG. EWSR1 encodes a nuclear 
protein of unknown function. The fusion 
protein is comprised of the N-terminal por-
tion of the EWSR1 protein linked to the 
DNA binding domain of FLI1. The chimeric 
protein has transforming activity in cell 
culture assays, but much remains to be 
learned about the biochemical properties 
of the fusion gene.
Despite the incomplete nature of our 
understanding of the biochemistry and 
cell biology of ES, it seems safe to con-
clude that the translocation that produces 
EWS/FLI is the key genetic event in the 
development of this cancer and that the 
presence of EWS/FLI transforms cells in 
large part through transcriptional dysregu-
lation. From this perspective, ES biology 
resembles that of many leukemias and 
other sarcomas that arise as the conse-
quence of chromosome translocations 
encoding chimeric transcription factors cancer cell May 2006 (Helman and Meltzer, 2003). Interestingly, 
both FLI1 and ERG can act as leukemia 
oncogenes. The burning question in ES 
biology then becomes the elucidation of 
the mechanism by which EWS/FLI leads 
to malignant transformation. The answer, 
it seems, must lie in the pattern of gene 
expression driven by EWS/FLI and the 
specific pathways that are dysregulated 
as a result. Of course, the hope is that 
essential EWS/FLI target genes will be 
identified and that these may guide the 
development of new therapies for ES.Determining genes associated 
with EWS/FLI-mediated malignant 
 transformation
While this seems like a fairly straightfor-
ward research agenda, there is no way 
to introduce EWS/FLI into ES progeni-
tor cells, since their nature is unknown. 
Even though many EWS/FLI targets have 
been found in heterologous models sys-
tems, studies in surrogates such as NIH 
3T3 cells are not completely satisfactory, 
since the effects of EWS/FLI may well 
be context dependent, and heterologous Figure 1. Ewing’s sarcoma arises from an unknown progenitor cell that acquires the EWS/FLI 
translocation
The translocation-bearing cell ultimately gives rise to clinically evident Ewing’s sarcoma as a 
consequence of the effects of EWS/FLI on gene expression and, most likely, the acquisition of 
additional genetic alterations. In order to identify a gene expression signature associated with 
EWS/FLI, the fusion gene was targeted with a stably expressed shRNa. This caused loss of trans-
formation, which could be rescued by an inducible EWS/FLI expression construct. Microarray 
expression analysis was used to monitor the effect of these manipulations. The resulting EWS/FLI 
signature was compared with the expression signature of Ewing’s sarcoma tumors. NKX2.2 was 
identified by this bioinformatics analysis and then targeted with a shRNa. This caused loss of the 
transformed phenotype in several ES cell lines, suggesting that its expression is driven (directly or 
indirectly) by EWS/FLI and that it is essential for the oncogenic properties of EWS/FLI. This strategy 
could in principle be applied to other similar fusion genes.331
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the biology of ES (Deneen et al., 2003). 
This is a general problem that plagues 
investigators studying the biology of 
fusion proteins in other systems where it 
may be difficult or impossible to obtain the 
appropriate precursor cell population for 
gene transfer studies. The advent of RNA 
interference has opened up a new realm 
of possibilities. Knocking down EWS/FLI 
expression in ES cells becomes a very 
attractive option, and it is this approach 
that has been taken by Smith et al. (2006). 
They identified an ES cell line, A673, that 
tolerates silencing EWS/FLI by a shRNA 
construct targeted to the 3′ UTR of FLI1 
(FLI1 itself is not expressed in these cells). 
A673 cells that express the EWS/FLI 
shRNA construct still can be cultured, but 
they lose their transformed phenotype, as 
evidenced by diminished clonogenicity in 
soft agar and loss of xenograft tumori-
genicity in mice. These phenotypic effects 
were reversed by rescue with an inducible 
EWS/FLI construct. The availability of this 
“inducible rescue” system allowed Smith 
et al. to use expression microarrays to 
examine the effects of silencing and then 
restoring EWS/FLI expression (Figure 1). 
The result is a list of genes (both down-
regulated and upregulated by EWS/FLI) 
that, at least in this cell line, can be placed 
downstream of EWS/FLI. Although it is 
impossible for Smith et al. to say which of 
these are direct targets of EWS/FLI, the 
EWS/FLI expression signature does show 
significant overlap with that of ES tumors 
by bioinformatics analysis (Khan et al., 
2001). Moreover, even simple inspection 
of their gene list reveals genes that are 
well known to be expressed in ES such, as 
the neuropeptide Y receptor. These results 
are also consistent with the observations 
of others (Hu-Lieskovan et al., 2005) who 
found that expression of EWS/FLI in a 
rhabdomyosarcoma cell line induced neu-
ral markers. Taken together, these findings 
suggest that the neural phenotype of ES 
may be a consequence of EWS/FLI activ-
ity rather than a direct clue to the identity 
of the ES progenitor cell.
Importance of NKX2.2 in EWS/FLI-
mediated tumorigenicity
If the transforming effects of EWS/FLI 
are a consequence of dysregulated gene 
expression, then the list of genes that 
constitute the EWS/FLI signature should 332 contain important mediators of this proc-
ess. Smith et al. tested one of these can-
didates, the homeobox gene NKX2.2, 
in some detail. They demonstrated that 
silencing NKX2.2 in A673 cells causes 
loss of clonogenicity in soft agar and loss 
of tumorigenicity in mice. Moreover, the 
same effect is observed in other ES cell 
lines, suggesting that NKX2.2 may indeed 
be of general importance as a mediator 
of EWS/FLI transformation. Interestingly, 
published ES tumor expression profiles 
demonstrate frequent expression of 
NKX2.2 (Baird et al., 2005). However, 
forced expression of NKX2.2 is not suf-
ficient to rescue the effects of EWS/FLI 
silencing in A673 cells, leading Smith et 
al. to conclude that NKX2.2 is necessary 
but not sufficient for the growth of ES. 
Although homeobox genes are known 
oncogenes in certain cancers, NKX2.2 
has never been associated with tumori-
genesis. This observation opens up the 
possibility of reconstructing the regula-
tory cascade downstream of EWS/FLI. If 
NKX2.2 is indeed a mediator of EWS/FLI 
transformation, then it can be predicted 
that some portion of the EWS/FLI gene 
signature should consist of genes that are 
direct targets of NKX2.2.
Broader applications of the “inducible 
rescue” approach
Although ES is a rare tumor, the impor-
tance of this study extends beyond its 
contribution to our understanding of ES 
itself. First, it should be noted that the 
“inducible rescue” approach taken by 
Smith et al. can, in principle, be general-
ized to any of the myriad of oncogenes 
that have been identified in any cancer 
and may prove to be particularly well 
suited to the many oncogenes that act as 
transcription factors. By combining two 
of the most powerful new technologies 
in cancer research, RNAi and microar-
ray analysis, it should prove possible to 
dissect the regulatory networks down-
stream of any oncogene and to do this in 
a reasonably authentic cellular context. 
Second, insights into the transforming 
actions of ETS family fusion genes are 
of broad relevance. Although the role of 
ETS genes in leukemogenesis has long 
been known, very recently they have 
been linked to prostate cancer by the 
discovery of ETS gene fusions in that 
disease (Tomlins, et al., 2005), raising the possibility that such gene fusions 
are more important in the common solid 
tumors than previously thought. Indeed, 
ETS gene fusions in prostate cancer now 
appear to be the most common onco-
genic translocation known. In this con-
text, the oncogenic mechanisms of ETS 
gene fusions takes on a new and broader 
importance. The results of Smith et al. 
demonstrate a general approach to sys-
tematically define those mechanisms and 
identify pathways that can be therapeuti-
cally targeted in cancers that are driven 
by oncogenic transcription factors.
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